A small retrospective study of women receiving taxane therapy for breast or ovarian cancer while pregnancy showed no statistically significant outcomes in maternal or fetal health.
Read the abstract here
Related Topics
OCRA-Funded Research Makes Inroads Toward Effective CAR T-Cell Therapies
A research team, led by Dr. Ugo Cavallaro and supported by OCRA’s 2019 Collaborative Research Development Grant, made progress toward improving immunotherapies for ovarian cancer. Dr. Frances R. Balkwill, a … Continued
OCRA Co-authors Collaborative Study Identifying & Addressing Caregiver Needs
Leaders in the patient advocacy space came together for a wide-ranging study on the often-overlooked challenges faced by caregivers of cancer patients, with Tracy Moore, LCSW, who serves as Ovarian … Continued
OCRA-Funded Research Expands Impact of DNA and RNA Data
A study published in Nature Cancer details how OCRA-funded research has dramatically expanded the impact of DNA and RNA data in the Cancer Genome Atlas and Cancer Cell Line Encyclopedia, … Continued